IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025
Iradimed Corporation (NASDAQ: IRMD) has scheduled its second quarter 2025 financial results conference call for August 1, 2025. The company will release its financial results before the market opens, followed by a management-hosted conference call at 11:00 a.m. Eastern Time.
Participants can join the call by registering through the provided link, after which they will receive dial-in details and a unique pin. The call will also be available via live webcast on the company's investor relations website, with a recording accessible afterward.
Iradimed Corporation (NASDAQ: IRMD) ha programmato la conference call per la presentazione dei risultati finanziari del secondo trimestre 2025 per il 1° agosto 2025. La società pubblicherà i risultati finanziari prima dell'apertura del mercato, seguita da una conference call condotta dal management alle 11:00 ora della costa orientale.
I partecipanti potranno unirsi alla chiamata registrandosi tramite il link fornito, dopo di che riceveranno i dettagli per la chiamata e un codice PIN unico. La chiamata sarà inoltre disponibile in diretta streaming sul sito web delle relazioni con gli investitori della società, con una registrazione accessibile successivamente.
Iradimed Corporation (NASDAQ: IRMD) ha programado su conferencia telefónica para presentar los resultados financieros del segundo trimestre de 2025 para el 1 de agosto de 2025. La empresa publicará sus resultados financieros antes de la apertura del mercado, seguida de una llamada gestionada por la dirección a las 11:00 a.m. hora del Este.
Los participantes pueden unirse a la llamada registrándose a través del enlace proporcionado, tras lo cual recibirán los detalles para marcar y un PIN único. La llamada también estará disponible mediante una transmisión en vivo en el sitio web de relaciones con inversores de la compañía, con una grabación accesible posteriormente.
Iradimed Corporation (NASDAQ: IRMD)� 2025� 8� 1일에 2025� 2분기 재무 실적 컨퍼런스 콜을 예정하고 있습니다. 회사� 시장 개장 전에 재무 실적� 발표하며, 이후 경영� 주최� 컨퍼런스 콜이 동부 표준� 오전 11�� 진행됩니�.
참가자는 제공� 링크� 통해 등록� � 전화 접속 정보와 고유 PIN� 받게 됩니�. 컨퍼런스 콜은 회사 투자� 관� 웹사이트에서 라이� 웹캐스트로도 제공되며, 이후 녹음본도 이용� � 있습니다.
Iradimed Corporation (NASDAQ : IRMD) a programmé sa conférence téléphonique pour les résultats financiers du deuxième trimestre 2025 le 1er août 2025. La société publiera ses résultats financiers avant l'ouverture du marché, suivie d'une conférence téléphonique animée par la direction à 11h00 heure de l'Est.
Les participants peuvent rejoindre l'appel en s'inscrivant via le lien fourni, après quoi ils recevront les détails pour se connecter ainsi qu'un code PIN unique. L'appel sera également disponible en webcast en direct sur le site des relations investisseurs de la société, avec un enregistrement accessible par la suite.
Iradimed Corporation (NASDAQ: IRMD) hat seine Telefonkonferenz zur Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 1. August 2025 angesetzt. Das Unternehmen wird die Finanzergebnisse vor Börsenöffnung veröffentlichen, gefolgt von einer von der Geschäftsführung geleiteten Telefonkonferenz um 11:00 Uhr Eastern Time.
Teilnehmer können sich über den bereitgestellten Link registrieren, woraufhin sie Einwahldaten und eine individuelle PIN erhalten. Die Telefonkonferenz wird außerdem als Live-Webcast auf der Investor-Relations-Webseite des Unternehmens verfügbar sein, mit einer anschließenden Aufzeichnung.
- None.
- None.
ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, . Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at . A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI�) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV�) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
